BEST study: one-year descriptive follow-up of bevacizumab treatment in hereditary haemorrhagic telangiectasia post-BABH interventional study. - Dupuis-Girod S; Decullier E; Rivière S; Lavigne C; Grobost V; Leguy-Seguin V; Maillard H; Chinet T; Fargeton AE; Guilhem A; Hermann R (Therapeutic advances in hematology, 2025)